ReproCell Inc
TSE:4978
Intrinsic Value
ReproCELL Inc. engages in stem cell research. [ Read More ]
The intrinsic value of one ReproCell Inc stock under the Base Case scenario is 159.7 JPY. Compared to the current market price of 155 JPY, ReproCell Inc is Undervalued by 3%.
Valuation Backtest
ReproCell Inc
Run backtest to discover the historical profit from buying and selling ReproCell Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ReproCell Inc
Current Assets | 7.2B |
Cash & Short-Term Investments | 6.4B |
Receivables | 391.9m |
Other Current Assets | 466.9m |
Non-Current Assets | 1.1B |
Long-Term Investments | 960.6m |
PP&E | 126.8m |
Intangibles | 25.3m |
Other Non-Current Assets | 33.9m |
Current Liabilities | 580.1m |
Accounts Payable | 119.1m |
Accrued Liabilities | 4.8m |
Other Current Liabilities | 456.3m |
Non-Current Liabilities | 47.3m |
Other Non-Current Liabilities | 47.3m |
Earnings Waterfall
ReproCell Inc
Revenue
|
2.5B
JPY
|
Cost of Revenue
|
-1.4B
JPY
|
Gross Profit
|
1.1B
JPY
|
Operating Expenses
|
-1.5B
JPY
|
Operating Income
|
-438.3m
JPY
|
Other Expenses
|
220.8m
JPY
|
Net Income
|
-217.5m
JPY
|
Free Cash Flow Analysis
ReproCell Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
ReproCell Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
ReproCell Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
ReproCell Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
ReproCell Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
ReproCell Inc
According to Wall Street analysts, the average 1-year price target for ReproCell Inc is 270 JPY .
Shareholder Return
Price
ReproCell Inc
Average Annual Return | 15.54% |
Standard Deviation of Annual Returns | 59.37% |
Max Drawdown | -69% |
Market Capitalization | 13.2B JPY |
Shares Outstanding | 87 662 444 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken and currently employs 106 full-time employees. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.
Contact
IPO
Employees
Officers
The intrinsic value of one ReproCell Inc stock under the Base Case scenario is 159.7 JPY.
Compared to the current market price of 155 JPY, ReproCell Inc is Undervalued by 3%.